Once daily Busulfan (Bu) and fludarabine (Flu) with allogeneic stem cell transplantation (AlloSCT) in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS): Clinical results and pharmacokinetics.

被引：0
|
作者：
de Lima, M
Madden, T
Couriel, D
Thall, RF
Shahjahan, M
Giralt, S
Anderlini, P
Russell, J
Shpall, EJ
Champlin, RE
Andersson, BS
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantation, Houston, TX 77030 USA
[2] MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2607
引用
收藏
页码：704A / 705A
页数：2
相关论文
共 50 条
  • [31] Allogeneic haematopoietic stem cell transplantation for elderly patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): A single center analysis
    Katayama, Y.
    Iwato, K.
    Ohchi, T.
    Okatani, T.
    Imanaka, R.
    Kyo, K.
    Itagaki, M.
    Katsutani, S.
    Kyo, T.
    Asaoku, H.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S475 - S476
  • [32] Prognostic factors for allogeneic stem cell transplantation (ASCT) for untreated first relapse of acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS)
    Alamo, JG
    Shahjahan, M
    Wong, RS
    de Lima, M
    Khouri, I
    Gajewski, J
    Couriel, D
    Andersson, BS
    Anderlini, P
    Champlin, R
    Giralt, S
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 38 - 39
  • [33] Lack of impact of comorbidities on outcomes of allogeneic stem cell transplantation (ASCT) for refractory acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS)
    Wong, RS
    Shahjahan, M
    Alamo, J
    de Lima, M
    Khouri, I
    Gajewski, J
    Andersson, B
    Champlin, R
    Giralt, S
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 31 - 31
  • [34] Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)
    Kröger, N
    Shimoni, A
    Zabelina, T
    Schieder, H
    Panse, J
    Ayuk, F
    Wolschke, C
    Renges, H
    Dahlke, J
    Atanackovic, D
    Nagler, A
    Zander, A
    BONE MARROW TRANSPLANTATION, 2006, 37 (04) : 339 - 344
  • [35] Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia
    Bibawi, S
    Abi-Said, D
    Fayad, L
    Anderlini, P
    Ueno, NT
    Mehra, R
    Khouri, I
    Giralt, S
    Gajewski, J
    Donato, M
    Claxton, D
    Braunschweig, I
    van Besien, K
    Andreeff, M
    Andersson, BS
    Estey, EH
    Champlin, R
    Przepiorka, D
    AMERICAN JOURNAL OF HEMATOLOGY, 2001, 67 (04) : 227 - 233
  • [36] Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
    Pusic, Iskra
    Choi, Jaebok
    Fiala, Mark A.
    Gao, Feng
    Holt, Matthew
    Cashen, Amanda F.
    Vij, Ravi
    Abboud, Camille N.
    Stockerl-Goldstein, Keith E.
    Jacoby, Meghan A.
    Uy, Geoffrey L.
    Westervelt, Peter
    DiPersio, John F.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (10) : 1761 - 1769
  • [37] Allogeneic stem cell transplantation (SCT) in children with myelodysplastic syndrome (MDS):: Results of myeloablative therapy with busulfan, cyclophosphamide and melphalan
    Locatelli, F
    Hoogerbrugge, P
    Peters, C
    Bender-Götze, C
    Giraldi, E
    Cecca, M
    Dini, G
    Klingebiel, T
    Zintl, F
    Nürnberger, W
    Messina, C
    Kremens, B
    Pession, A
    Stary, J
    van Wering, E
    Mann, G
    Rogge, T
    Fischer, A
    Zimmermann, M
    Niemeyer, C
    BONE MARROW TRANSPLANTATION, 1999, 23 : S152 - S152
  • [38] Once-daily intravenous busulfan in children undergoing conditioning for stem cell transplantation: pharmacokinetics and clinical results
    Bredius, RGM
    Zwaveling, J
    den Hartigh, J
    Boelens, J
    Lankester, AC
    Wulffraat, NM
    Guchelaar, HJ
    Egeler, RM
    BONE MARROW TRANSPLANTATION, 2006, 37 : S202 - S202
  • [39] Once-daily intravenous busulfan in children undergoing conditioning for stem cell transplantation: pharmacokinetics and clinical results
    Zwaveling, J
    den Hartigh, J
    Boelens, JJ
    Lankester, AC
    Guchelaar, HJ
    Egeler, M
    Bredius, RG
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (04) : 486 - 486
  • [40] Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome
    Gao, Li
    Gao, Lei
    Gong, Yi
    Zhang, Cheng
    Chen, Xing-Hua
    Zhang, Xi
    LEUKEMIA RESEARCH, 2013, 37 (11) : 1482 - 1487
12345